I had this very thought while doing my PhD. Why are these guidelines in PDFs and not some other structured format that can be leveraged by systems/tools. Thanks for the write up, lovely read.
Yes, but... What happens when the research is not replicable, has errors, or is outright fraudulent? We like to think these are edge cases. However, some of the stats are concerning. How do you only scale the "good" research?
Retired oncologist here with a background in applied AI. I agree with your sentiment and would be interesting in working together on a novel approach, different from vendor-driven top-down decision support. Hospitals and private equity love these, but I think doctors really want something else. I have some thoughts on this, and am always interested in exchanging ideas.
Nice article.
It’s a problem we solved with software and subject matter expert curated rules along with FDA and clinical trials on top of NCCN.
Powers our platform for decision support, trial optimization and NGS reporting.
Email address below if anyone wants to learn more.
Ian Maurer
CTO, GenomOncology
ian @ genomoncology.com
There you go. Just another group extracting more money from the health care system. How about just doing it like Sean? Just to help people...
I had this very thought while doing my PhD. Why are these guidelines in PDFs and not some other structured format that can be leveraged by systems/tools. Thanks for the write up, lovely read.
Yes, but... What happens when the research is not replicable, has errors, or is outright fraudulent? We like to think these are edge cases. However, some of the stats are concerning. How do you only scale the "good" research?
Interesting read; the NHS needs thought like this
Retired oncologist here with a background in applied AI. I agree with your sentiment and would be interesting in working together on a novel approach, different from vendor-driven top-down decision support. Hospitals and private equity love these, but I think doctors really want something else. I have some thoughts on this, and am always interested in exchanging ideas.